Market overview
Stroke is one of the most common causes of death globally and the leading cause of long-term disability in adults. The global market for all stroke indications, including diagnostics and treatments, was estimated at around USD 38.98 billion in 2024, and is expected to reach USD 83.91 billion by 2034. at an annual growth rate (CAGR) of 7.96%. This growth is being driven by an increased incidence of stroke, particularly in an ageing population.
Precedence Research (2024)
SAH – Subarachnoid Hemorrhage
A life-threatening form of stroke with a high mortality rate.
There are currently no approved neuroprotective treatments.
Only one authorised drug (nimodipine) with limited efficacy.
Patients are on average 20-30 years younger than those patients suffering an ischemic stroke.
High burden of care and costs to society.
Indirect costs account for rehab, loss of work, etc.
Market size and addressable population
More than 100,000 patients in the EU, USA and Japan (annual incidence).
Xplico, commissioned market analysis (2025)
Willingness to pay and price levels
Anticipated price range per treatment: USD 15,000-30,000.
Xplico, commissioned market analysis (2025)
High willingness to pay due to severe consequences and lack of alternatives.
Potential price support through Orphan Drug Designation.
FI – Focal Ischemic Stroke
Most common form of stroke resulting in high mortality and disability.
There are currently no approved neuroprotective treatments.
Despite thrombolysis/ thrombectomy, there are no drugs to protect the brain.
High societal costs.
Indirect costs account for rehab, loss of productivity, etc.
Market size and addressable population
Approx. 1.6 million patients in the EU and USA (annual incidence).
Xplico, commissioned market analysis (2025)
Willingness to pay and price levels
Anticipated price range per treatment: USD 10,000-20,000.
Xplico, commissioned market analysis (2025)
High willingness to pay due to severe consequences and lack of alternatives.
GI – Global Cerebral Ischemic Stroke
There are currently no approved neuroprotective treatments.
Treatment limited to intensive care and supporting efforts.
Survivors often suffer severe neurological damage.
High burden of care and societal costs.
Indirect costs account for rehab, loss of work, etc.
Market size and addressable population
More than 700,000 patients in the EU and USA (annual incidence).
Willingness to pay and price levels
Anticipated price range per treatment: USD 10,000-20,000.
Xplico, commissioned market analysis (2025)
High willingness to pay due to severe consequences and lack of alternatives.
Potential price support through Orphan Drug Designation.
Contact
Medicon Village
223 81 Lund. Sweden
info@edvince.com